Verve Therapeutics Inc. (VERV)
Verve Therapeutics Statistics
Share Statistics
Verve Therapeutics has 88.8M shares outstanding. The number of shares has increased by 5.75% in one year.
| Shares Outstanding | 88.8M |
| Shares Change (YoY) | 5.75% |
| Shares Change (QoQ) | 4.88% |
| Owned by Institutions (%) | 93.39% |
| Shares Floating | 66.12M |
| Failed to Deliver (FTD) Shares | 1K |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 16.63M, so 18.73% of the outstanding shares have been sold short.
| Short Interest | 16.63M |
| Short % of Shares Out | 18.73% |
| Short % of Float | 22.16% |
| Short Ratio (days to cover) | 15.72 |
Valuation Ratios
The PE ratio is -2.39 and the forward PE ratio is -2.03. Verve Therapeutics's PEG ratio is 0.1.
| PE Ratio | -2.39 |
| Forward PE | -2.03 |
| PS Ratio | 14.69 |
| Forward PS | 25.8 |
| PB Ratio | 0.96 |
| P/FCF Ratio | -2.94 |
| PEG Ratio | 0.1 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Verve Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.65, with a Debt / Equity ratio of 0.14.
| Current Ratio | 12.65 |
| Quick Ratio | 12.65 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | -0.31 |
| Debt / FCF | -0.43 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $118K |
| Profits Per Employee | $-725.22K |
| Employee Count | 274 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 349K |
| Effective Tax Rate | -0.18% |
Stock Price Statistics
The stock price has increased by -7.56% in the last 52 weeks. The beta is 1.87, so Verve Therapeutics's price volatility has been higher than the market average.
| Beta | 1.87 |
| 52-Week Price Change | -7.56% |
| 50-Day Moving Average | 5.67 |
| 200-Day Moving Average | 5.9 |
| Relative Strength Index (RSI) | 60.36 |
| Average Volume (20 Days) | 2.65M |
Income Statement
In the last 12 months, Verve Therapeutics had revenue of 32.33M and earned -198.71M in profits. Earnings per share was -2.36.
| Revenue | 32.33M |
| Gross Profit | 32.33M |
| Operating Income | -228.66M |
| Net Income | -198.71M |
| EBITDA | -228.66M |
| EBIT | -228.66M |
| Earnings Per Share (EPS) | -2.36 |
Balance Sheet
The company has 172.56M in cash and 69.98M in debt, giving a net cash position of 102.58M.
| Cash & Cash Equivalents | 172.56M |
| Total Debt | 69.98M |
| Net Cash | 102.58M |
| Retained Earnings | -743.01M |
| Total Assets | 647.39M |
| Working Capital | 499.84M |
Cash Flow
In the last 12 months, operating cash flow was -157.69M and capital expenditures -3.74M, giving a free cash flow of -161.43M.
| Operating Cash Flow | -157.69M |
| Capital Expenditures | -3.74M |
| Free Cash Flow | -161.43M |
| FCF Per Share | -1.92 |
Margins
Gross margin is 100%, with operating and profit margins of -707.23% and -614.59%.
| Gross Margin | 100% |
| Operating Margin | -707.23% |
| Pretax Margin | -613.51% |
| Profit Margin | -614.59% |
| EBITDA Margin | -707.23% |
| EBIT Margin | -707.23% |
| FCF Margin | -499.28% |
Dividends & Yields
VERV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for VERV is $24, which is 317.4% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24 |
| Price Target Difference | 317.4% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 0.03 |
| Piotroski F-Score | 3 |